BioCentury
ARTICLE | Company News

CHMP interactions delaying Coherus biosimilar timeline

June 25, 2018 10:56 PM UTC

Coherus Biosciences Inc. (NASDAQ:CHRS) lost $1.80 (10%) to $15.40 on Monday after it disclosed that EMA's CHMP will require further interactions with the company in order to issue an opinion on its pending MAA for CHS-1701, its biosimilar of Neulasta pegfilgrastim.

Coherus said it expects the interactions to occur prior to the next CHMP meeting, scheduled for July 23-26. The company said last month it was anticipating a CHMP opinion on or before June 28...